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Introduction
Dry eye disease (DED), also known as keratoconjunctivitis 
sicca (KCS), is a very common condition that often prompts 
patients to seek help from eye-care professionals. In the 
past decade, understanding of the multifactorial aetiology 
of this disease has improved considerably, permitting the 
development of specific therapeutic options to treat the 
condition more effectively.
The purpose of this review is to provide the family practitioner 
with an updated insight into the pathophysiology, clinical 
picture, and treatment options of DED to facilitate confident 
assessment and management of this often under-diagnosed 
condition.
Definition
For many years, DED was considered to be the result of 
a simple imbalance between tear production and tear 
evaporation. However, understanding of the disease has 
improved significantly, and now permits the formulation of a 
far more accurate definition. 
In 2007, the International Dry Eye Workshop (DEWS) 
compiled the following definition: 
“Dry eye is a multifactorial disease of the tears and ocular 
surface, which results in symptoms of discomfort, visual 
disturbance, and tear film instability, with potential damage 
to the ocular surface. It is accompanied by increased 
osmolarity of the tear film and inflammation of the ocular 
surface.”1 
It is clear from this definition that dryness of the ocular 
surface is only one component of the disease. The term 
“dysfunctional tear syndrome” (DTS) provides a more 
accurate description of the condition, but has not, as yet, 
superseded the use of the term “DED”.2
Demographics
DED most commonly occurs in postmenopausal women 
and in the elderly, with the reported prevalence varying from 
7.4-33.7% in different studies.3-6 Patients with autoimmune 
disease have a higher prevalence of DED than the general 
population.7 Other factors, such as cigarette smoking 
and pterygium, are also associated with an increased 
prevalence.8
Pathophysiology
It is traditionally taught that the precorneal tear film consists 
of three distinct sandwiched layers. The outer lipid layer is 
secreted by the meibomian glands in the eyelids, the middle 
aqueous layer is secreted mainly by the lacrimal glands, 
and the inner mucin layer originates from the conjunctival 
goblet cells.9 Recent reports suggest a more complex 
model, where the tear film forms a dynamic mucinous 
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gel, although the role played by each component remains 
largely unchanged.10
The outer lipid layer stabilises the tear film and prevents 
evaporation. Therefore, a deficient lipid layer may cause 
evaporative dry eye (EDE). The middle aqueous layer 
supplies dissolved atmospheric oxygen to the corneal 
epithelium. It washes any unwanted substances from the 
ocular surface, and also contains antimicrobial proteins, 
such as lysozyme, lactoferrin and immunoglobulin A. 
Decreased production of the aqueous layer causes aqueous 
deficiency dry eye (ADDE). The inner mucin layer enables 
the aqueous layer to attach itself to the corneal epithelium 
by converting the hydrophobic epithelial surface to one that 
is hydrophilic. Deficiency of the mucin layer occurs when 
conjunctival goblet cells are damaged.
Tear film instability may result from any alteration in its normal 
composition. A change in either the quality, or quantity, of 
any important tear film constituent, will destabilise the tear 
film, and lead to symptoms of DED. These changes are often 
caused by an inflammatory process affecting the meibomian 
glands, the conjunctival goblet cells, the lacrimal glands, 
or any combination of these structures. This underlying 
inflammation is usually mediated by T lymphocytes, and 
may occur in patients both with, and without, a systemic 
inflammatory disease.11,12
It is important to note that tear film instability allows the 
precorneal tear film to break up sooner than it normally 
would. This leads to the formation of transient, microscopic 
dry areas on the corneal surface, which causes the eye to 
feel dry or gritty. However, these dry areas may also stimulate 
the reflex secretion of aqueous tears by the lacrimal glands 
in an effort to decrease the perceived dryness, and thereby 
cause the paradoxical tearing that patients with DED 
often complain about. This illustrates why DTS is a better 
term than DED, since the problem is caused by tear film 
dysfunction, rather than by a mere lack of tears.
Classification, causes and risk factors
As indicated above, DED is often divided into two main 
classes, namely EDE and ADDE, although many patients 
experience a combination of the two. Table I provides more 
detail regarding specific conditions that predominantly 
cause either EDE or ADDE.9
Several other factors have also been identified that have 
a significant effect on dry eye symptoms. Many of these 
factors exacerbate the symptoms, while some tend to 
alleviate them. 
Table II provides a summary of these factors.7,12
It is especially important for family practitioners to be aware 
of the multitude of systemic medications that may cause, or 
worsen, the symptoms of DED. Table III highlights a number 
of drugs associated with dry eye symptoms.10
Table I: Classification and causes of dry eyes
Classification Causes
Aqueous deficiency dry eye
Sjögren syndrome 
Other causes
Neurological Decreased sensation (contact 
lens wear, refractive surgery)
Parkinson’s Disease
Decreased lacrimal tissue function Surgical removal
Tumour
Inflammation
Congenital absence (rare)
Obstructed lacrimal ductules Chemical burns
Stevens-Johnson syndrome
Ocular cicatricial pemphigoid
Age-related hyposecretion
Vitamin A deficiency
Evaporative dry eye
Meibomian gland disease Blepharitis
Rosacea
Atopic keratoconjunctivitis
Prolonged exposure Severe proptosis
Facial nerve palsy
Eyelid scarring
Environmental factors Air conditioning
Dry, windy conditions
Contact lens wear
Adapted from reference 9
Table II: External factors that increase, or relieve, dry eye symptoms
 Increase symptoms  Relieve symptoms
Increasing age Increased intake of omega-3 fatty 
acids
Female sex High ambient relative humidity
Hormone replacement therapy 
(oestrogen alone)
Long-term contact lens wear
Systemic medications
Refractive surgery (LASIK,a PRKb)
Smoking and alcohol use
Extended visual tasks (reading, 
computer work)
a = laser-assisted in-situ keratomileusis, b = photo refractive keratectomy
Adapted from references 7 and 12
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Clinical features
Patients often complain about a feeling of dryness, 
grittiness, or burning, that tends to get worse during the 
day. They may also report transient blurring of vision, or 
increased tearing.
The signs are often very subtle, and may not match the 
severity of the presenting complaints. Findings may vary 
from a completely normal-looking eye, to one with variable 
crusting or foaming on the eyelid margins, mild conjunctival 
redness, or punctate staining of the cornea when viewed 
under cobalt blue light, after the installation of fluorescein 
dye (Figure 1). Corneal epithelial defects, and even corneal 
perforation, may occur in severe cases.
Several different symptom questionnaires have been 
designed to aid busy practitioners in the diagnosis of DED, 
and these may be extremely useful when a diagnosis of 
DED is suspected, but little evidence is found on clinical 
examination. The Ocular Surface Disease Index© (OSDI), for 
example, asks a patient 12 simple questions, and then allows 
the practitioner to decide whether or not DED is present, 
and if so, to grade the severity thereof. It has been shown 
to discriminate effectively between normal eyes, eyes with 
mild-to-moderate DED, and eyes with severe DED. It may 
also be used to monitor the response to any treatment that 
the patient receives.13 An example of the OSDI is available 
at www.dryeyezone.com/documents/osdi.pdf
Treatment options
DED treatment aims to improve quality of life by relieving 
the symptoms, and enhancing visual acuity. It also aims to 
restore the normal homeostasis of the ocular surface and 
tear film, and to address any underlying disease processes.1 
Several treatment options are available, and the appropriate 
choice is based on the severity of the patient’s symptoms, 
as elicited from the taking of a clinical history, or completion 
of a symptom questionnaire, or both.
Mild cases
These cases are ideally suited to management by a family 
practitioner, since the necessary interventions include 
lifestyle changes, dietary measures, a review of systemic 
medications, and the initiation of topical lubricants. The 
recommended lifestyle and dietary adjustments are 
summarised in Table IV.
Table IV: Recommended lifestyle and dietary changes for patients with 
dry eye disease
Avoid allergens and control 
allergies
Humidify the home and work 
environment
Beware of heaters, air-conditioners
Avoid rubbing the eyes
Stop smoking Reduce exposure to environmental 
smoke
Limit periods of television 
watching, reading 
Encourage frequent breaks
Use artificial tears during the 
activity
Ensure correct use of contact 
lenses
Encourage a diet rich in omega-3 
fatty acids
Eat fish (salmon, mackerel, 
sardines, tuna)
Plant oils (canola oil, flax seed oil)
Reduce alcohol consumption
Adapted from reference 10
Systemic drugs implicated in causing or exacerbating dry 
eye symptoms should, if possible, be replaced with more 
suitable alternatives, and the patient should be given artificial 
tear drops to supplement their precorneal tear film. These 
Table III: Systemic drugs associated with dry eye symptoms
Drug class Examples
Antiarrhythmia Amiodarone
Antihistamine Diphenhydramine, hydroxyzine
Anti-Parkinson Benztropine, trihexyphenidyl
Antipsychotics Chlorpromazine, haloperidol
Antispasmodics Hyoscine butylbromide, oxybutinin
Tricyclic antidepressants Amitriptyline, nortriptyline
Diuretics Hydrochlorothiazide
Beta blockers Atenolol
Retinoids Isotretinoin
Sex hormones Estrogen supplements
Selective serotonin-reuptake 
inhibitors
Fluoxetine, paroxetine, sertraline
Chemotherapy Cyclophosphamide, 5-fluorouracil
Adapted from reference 10
Figure 1: Punctate staining of the cornea when viewed under cobalt blue 
light, after the installation of fluorescein dye
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preparations usually contain hypromellose, carmellose, 
polyvinyl alcohol or polyacrylic acid. It should be noted 
that a preservative such as benzalkonium chloride, which 
is found in many ophthalmic drops, may also contribute 
to dry eye symptoms if used more than four times a day. 
Therefore, patients should change to preservative-free 
preparations if they require more frequent application to 
control their symptoms.
Moderate cases
Patients with moderate symptoms of DED require the 
same initial management as those with mild disease. 
However, they are likely to require more frequent 
application of topical lubricants, and should be given 
preservative-free drops from the outset. Oral omega-3 
fatty acid supplements may also be prescribed if dietary 
intake is not sufficient. If symptoms persist despite all the 
treatment modalities already employed, referral should 
be considered for slit lamp examination, and other 
special investigations. This will allow more specific and 
individualised management of the underlying problem.
For instance, if significant eyelid inflammation is present, 
a combination of short-term topical antibiotics and 
long-term, low-dose oral tetracycline may be indicated. 
If aqueous deficiency is diagnosed, patients may also 
require plugging, or cautery of the lacrimal puncta, to 
decrease tear drainage. Ocular surface inflammation 
should also be addressed by the initial prescription of 
low-potency corticosteroids, such as fluorometholone. 
If effective, the corticosteroids may later be replaced 
by cyclosporine A, which prevents T-cell activation and 
has been shown to improve DED both subjectively and 
objectively.12 Cyclosporine A is now commonly used by 
ophthalmologists in a topical preparation, as part of the 
treatment for moderate and severe DED.
Severe cases
Severe cases require specialist management. In 
addition to all the treatment modalities discussed so 
far, several other interventions may be needed. Patients 
may require moisture-retaining eyewear, or special 
contact lenses to preserve whatever aqueous tears they 
are able to produce themselves. They may also require 
the preparation of eye drops from their own serum, 
which contains a variety of anti-inflammatory factors. 
Many studies have shown a beneficial response to 
20% autologous serum drops, when used in patients 
with severe DED.10 Systemic immunosuppressive 
therapy should also be considered if the patient has an 
underlying systemic inflammatory condition. Surgical 
procedures, such as tarsorrhaphy, or even salivary 
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gland or duct transplantation, may become necessary in 
very severe cases.12
Conclusion
DED is very common, and poses a significant problem to 
its sufferers. It is now well established that this disease has 
a multi-factorial aetiology, and therefore requires several 
different modalities to treat it effectively. 
Symptom questionnaires are able to accurately diagnose 
and grade the severity of DED, and can assist healthcare 
practitioners in the management of this condition. 
Mild disease should preferably be managed by family 
practitioners, who are in an ideal position to assess and alter 
environmental, dietary, and iatrogenic factors that cause, or 
exacerbate, the disease. Moderate-to-severe DED generally 
requires more specialised intervention, thus the family 
practitioner should consider referral to an ophthalmologist.
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